CDK 4/6 Inhibitors: Evolution and Revolution in the Management of ER+ Metastatic Breast Cancer

JCO Oncol Pract. 2022 May;18(5):329-330. doi: 10.1200/OP.21.00611. Epub 2021 Oct 12.

Authors

Priyanka M Reddy¹, James M Martin¹, Alberto J Montero¹

Affiliation

¹ Division of Hematology and Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH.

PMID: 34637353
DOI: 10.1200/OP.21.00611

No abstract available

Publication types

Comment

MeSH terms

Breast Neoplasms* / drug therapy
Breast Neoplasms* / pathology
Female
Humans